Ionis (IONS) Q2 Revenue Soars 101%
Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…
43,711$
2,01%
Echtzeit-Aktienkurs Ionis Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Ionis Pharmaceuticals Inc. Aktie
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
· Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute…
Ionis Pharmaceuticals - US-Biotechkonzern überzeugt mit starker Pipeline!
Geschäftstreiber: Der US-Biotech-Konzern Ionis Pharmaceuticals (IONS) hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen…
Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com
Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress…
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check…
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far…
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Heres What You Should Know
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this…
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA).…
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid…
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this…
Big Pipeline Updates From Kiniksa Pharmaceuticals
…
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the…
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do…
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus By Investing.com
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus…
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street…
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
…
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
The mean of analysts price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this…
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
…
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
…
Kiniksa Pharmaceuticals (KNSA) is on the Move, Heres Why the Trend Could be Sustainable
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that…
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
…
Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript
…
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
…
Kiniksa Pharmaceuticals Q2 2024 Earnings Preview
…
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)
…
Kiniksa Pharmaceuticals files for $400M mixed shelf
…
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –…
Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
…
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
…
Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024 By Investing.com
Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024…
Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP By Investing.com
Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP…